SCHEMBL3664707

SCHEMBL3664707

c1ccc(-c2cc(-c3cncc(-c4ccc(CNC5CCNC5)cc4)c3)cc(NC3CC3)n2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 6/20 0.42
TGFBR1 P36897 2/20 0.40
GPR39 O43194 1/20 0.38
IRAK4 Q9NWZ3 3/20 0.38
PRKD1 Q15139 2/20 0.38
PRKD2 Q9BZL6 2/20 0.38
PIM1 P11309 3/20 0.37
PIM2 Q9P1W9 2/20 0.37
PRKCI P41743 1/20 0.36
FLT3 P36888 2/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
DYRK1A Q13627 1/20 0.36
NRAS P01111 1/20 0.36
LCK P06239 1/20 0.36
RET P07949 1/20 0.36
PDGFRB P09619 1/20 0.36
CDK7 P50613 1/20 0.36
IRAK1 P51617 1/20 0.36
CCNH P51946 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192009 0.82 GPR39 (0.43) CCNT1GPR39PIM1PIM2FLT3
SCHEMBL3808218 0.82 ABL1 (0.44) CCNT1TGFBR1GPR39PRKD1PRKD2
SCHEMBL3714748 0.79 TGFBR1 (0.46) TGFBR1GPR39DYRK1A
SCHEMBL3663705 0.77 GPR39 (0.43) CCNT1GPR39PIM1PIM2FLT3
SCHEMBL3721636 0.76 ASIC3 (0.43) CCNT1GPR39IRAK4PIM1PIM2
SCHEMBL3717886 0.76 HRH3 (0.40) CCNT1TGFBR1GPR39PIM1CLK2
SCHEMBL4168192 0.76 HRH3 (0.40) CCNT1TGFBR1GPR39PIM1CLK2
SCHEMBL3722403 0.76 CCNC (0.51)
SCHEMBL3665002 0.75 GPR39 (0.47) CCNT1GPR39PIM1PIM2FLT3
SCHEMBL3718095 0.75 GPR39 (0.39) TGFBR1GPR39

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK CCNT1 247/4885TGFBR1 187/4885GPR39 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.